Author: Ravi Shankar

• Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone¹
• Benefit increased over time in invasive disease-free survival and across key secondary endpoints^1-3
• Patients off Kisqali for a median of three years, with clinical benefit continuing to deepen after treatment completion^1-3 

Basel, October 23, 2026 – Novartis today announced results from the six-year follow-up analysis of the Phase III NATALEE trial, reporting positive, clinically meaningful overall survival (OS) data with Kisqali^® (ribociclib) plus endocrine therapy (ET) compared to ET alone¹. The study was in the broadest early breast cancer (eBC) population of patients with stage II and III HR+/HER2- early breast cancer at high risk of recurrence, including those with high-risk node-negative (N0) disease and all node-positive patients^1,2. Kisqali plus ET reduced the risk of death by nearly 20% (19.1%) compared to ET alone (HR=0.809; 95% CI: 0.661-0.989), with consistent overall survival benefit observed across all key subgroups¹. These late-breaking results will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2026.

Patients have been off Kisqali for a median of three years (38 months) and have passed the five-year protocol-specified ET duration^1,2. The invasive disease-free survival (iDFS) benefit increased from 4.1% at five years to 5.3% at six years, underscoring the long-term value of dual inhibition, with benefit observed years after treatment completion^1,3.

Fewer patients treated with Kisqali plus ET experienced metastatic recurrence compared to ET alone, and OS continued to increase over time, with the absolute difference increasing from 1.2% at five years to 2.1% at six years^1,3. Breast-cancer specific survival (BCSS) was supportive of OS benefit, showing a ~30% reduction in risk of breast cancer-specific deaths (HR=0.709; 95% CI: 0.559-0.890) compared to ET alone¹.

Six-year NATALEE results reinforce long-term clinical benefit
“The NATALEE six-year data clearly demonstrate a clinically meaningful improvement in overall survival with ribociclib plus endocrine therapy,” said Dennis J. Slamon, MD, Chief of the Division of Hematology/Oncology, UCLA Department of Medicine. “These findings have very important implications for patients as well as health care providers worldwide and further strengthen the role of ribociclib in treating patients with HR+/HER2- early breast cancer at high risk of recurrence.”

Benefits observed across major efficacy endpoints, with sustained or increasing improvements over six years^1,3.

Endpoint	Hazard Ratio	95% CI	Absolute Benefit at 5Y	Absolute Benefit at 6Y
Overall Survival (OS)	0.809	0.661-0.989	1.2%	2.1%
Breast-Cancer Specific Survival (BCSS)	0.709	0.559-0.890	1.5%	2.6%
Invasive Disease-Free Survival (iDFS)	0.741	0.646-0.849	4.1%	5.3%
Distant Disease-Free Survival (DDFS)	0.744	0.646-0.858	3.7%	4.9%
Distant Recurrence-Free Survival (DRFS)	0.738	0.631-0.846	3.5%	4.4%

“The clinically meaningful overall survival benefit observed in NATALEE underscores Kisqali as a standard of care for eligible patients and its foundational role in early breast cancer treatment,” said Andrea Myers, Global Head, Oncology Development, Novartis, Ad Interim. “These findings demonstrate the value of combining CDK4/6i with endocrine therapy in the broadest population of patients at high risk of recurrence, including those with high-risk node-negative disease and all node-positive patients.”

With longer follow-up, the safety profile remained consistent with previous analyses, and no new safety signals were observed^1-3. Overall, rates of secondary primary malignancies (SPMs) were 3.0% with Kisqali plus ET and 3.3% with ET alone¹. SPMs leading to death were 0.2% in both the Kisqali plus ET and ET alone arms¹.

Building on established Kisqali overall survival evidence
Kisqali is the only CDK4/6 inhibitor to demonstrate statistically significant OS benefit across three randomized controlled trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) in metastatic breast cancer and clinically meaningful OS in the broadest early breast cancer population at high risk of recurrence, including node-negative and node-positive disease^1,4-14.

“For those diagnosed with early breast cancer who face a higher risk of recurrence, having meaningful long-term overall survival data is invaluable,” said Jean A. Sachs, Chief Executive Officer, Living Beyond Breast Cancer. “These new insights help with important, shared decision-making conversations with their medical team, and make clear the importance of continued research to support those navigating complex decisions.”

About NATALEE
NATALEE is a global Phase III, multi-center, randomized, open-label trial to evaluate the efficacy and safety of Kisqali with ET as an adjuvant treatment versus ET alone in the broadest range of patients with stage II and III HR+/HER2- eBC, being conducted in collaboration with TRIO^15,16. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin, if applicable^15,16. The primary endpoint of NATALEE is invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria^15,16. A total of 5,101 adult patients with HR+/HER2- eBC across 20 countries were randomized in the trial^15,16.

About Kisqali^® (ribociclib)
Kisqali^® (ribociclib) is a selective cyclin-dependent kinase inhibitor, helping slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, enable cancer cells to grow and divide quickly. Targeting CDK4/6 with enhanced precision plays a role in tumor control.

Kisqali has been approved as a treatment for breast cancer by regulatory authorities in more than 100 countries worldwide, including the US FDA and the European Commission^16,17. In the US, Kisqali is indicated in combination with an AI as an adjuvant treatment for adults with HR+/HER2- stage II and III eBC at high risk of recurrence, as well as for the treatment of adults with HR+/HER2- advanced or metastatic breast cancer (mBC) as initial ET; Kisqali is also approved in the metastatic setting in combination with fulvestrant as initial ET or following disease progression on ET¹⁶. In the EU, Kisqali is approved in combination with an AI for the adjuvant treatment of patients with HR+/HER2- eBC at high risk of recurrence; and for the treatment of women with HR+/HER2- locally advanced or mBC in combination with either an AI or fulvestrant as initial ET or following disease progression who have prior endocrine therapy¹⁷. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist^16,17.

In EBC, Kisqali is the only CDK4/6 inhibitor recommended by the NCCN Guidelines® for breast cancer as Category 1 preferred for both all node-positive disease as well as for patients with no nodal involvement with high-risk disease characteristics, such as tumor size >5 cm, or for tumors sized 2-5 cm, either Grade 2 with high genomic risk/Ki-67 ≥20% or Grade 3¹⁸. Kisqali approvals in eBC from regulatory authorities worldwide are ongoing, including recent approval from China’s National Medical Products Administration¹⁹. In mBC, Kisqali has consistently demonstrated statistically significant overall survival benefit across three Phase III trials^4-14. The NCCN Guidelines® also recommend Kisqali as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of people living with HR+/HER2- MBC when combined with an AI, making Kisqali the preferred first-line treatment of choice for US prescribers in HR+/HER2- mBC¹⁸.

In addition, Kisqali has achieved the highest score (A) on the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) for eBC; and has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of four out of five for first-line pre-menopausal patients with HR+/HER2- advanced breast cancer^20,21. Further, Kisqali in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for post-menopausal patients with HR+/HER2- advanced breast cancer treated in the first line²².

Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals.

About Novartis in Breast Cancer
For more than 30 years, Novartis has been at the forefront of driving scientific advancements for people touched by breast cancer and improving clinical practice in collaboration with the global community. With one of the most comprehensive breast cancer portfolios and pipeline, Novartis is an industry leader in the discovery of new therapies and combinations in HR+/HER2- breast cancer, the most common form of the disease.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Slamon D et al. Adjuvant ribociclib + nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer:  NATALEE 6-year overall survival and efficacy outcomes. Presented at the European Society of Medical Oncology (ESMO) Congress. October 23-27, 2026. Madrid, Spain.
2. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488
3. Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant Ribociclib Plus Nonsteroidal Aromatase Inhibitor Therapy in Patients With HR+/HER2− Early Breast Cancer: NATALEE 5-Year Outcomes. Presented at the European Society for Medical Oncology (ESMO) Congress; October 17-21, 2025; Berlin, Germany.
4. Yardley DA et al. Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials. Poster presented at the European Society of Medical Oncology Congress. September 9-13, 2022. Paris, France.
5. Neven P et al. Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Paris, France.
6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663.
7. Hortobagyi GN et al. Overall survival (OS) results from the phase III MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. LBA 17. Proffered paper presented at the European Society of Medical Oncology Congress, September 16-21, 2021. Lugano, Switzerland.
8. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765.
9. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524. doi:10.1056/NEJMoa1911149.
10. Slamon DJ et al. Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical Oncology Congress. September 29, 2019. Barcelona, Spain.
11. Slamon DJ et al. Updated overall survival (OS) results from the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Presented at the American Society of Clinical Oncology Annual Meeting. June 5, 2021. Chicago, USA.
12. Tripathy D et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at the San Antonio Breast Cancer Symposium. December 9, 2020. Texas, USA.
13. Yardley D et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of Clinical Oncology Annual Meeting. June 2020. Chicago, USA.
14. O’Shaughnessy J et al. Overall survival subgroup analysis by metastatic site from the Phase III MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with HR+/HER2− advanced breast cancer. Presented at the San Antonio Breast Cancer Symposium. December 7-10, 2021. Texas, USA.
15. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/ HER2- Early Breast Cancer (NATALEE). Accessed September 2026. https://clinicaltrials.gov/study/NCT03701334
16. Kisqali. Prescribing Information (US FDA). Novartis Pharmaceuticals Corporation; 2017. Accessed November 2025. https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf
17. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm Limited; 2017. Accessed November 2025. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf
18. NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) РBreast Cancer. Accessed November 2025. https://www.nccn.org
19. National Medical Products Administration. Drug Evaluation Information Disclosure: Drug Evaluation Approval Results. National Medical Products Administration. Published May 21, 2025. Accessed November 2025. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250521151427103.html
20. European Society of Medical Oncology (ESMO). ESMO MCBS scorecards; NATALEE. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-468-1 Accessed November 2025.
21. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated February 7, 2025. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1. Accessed November 2025.
22. European Society for Medical Oncology. Magnitude of Clinical Benefit Scale Scorecard. Updated February 7, 2025. Available from: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1. Accessed November 2025.

Novartis Media Relations
E-mail: media.relations@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

• Bombardier is expanding its presence across the country, hiring 800 people for jobs located in its home base of Kansas as well as Texas, Indiana, and Connecticut
• This strategy includes an initial phase of investment estimated at $270M earmarked for infrastructure growth
• Bombardier selects Texas as pillar of ongoing Services expansion with 150 high-skilled new jobs planned for the state; expands in Midwest with Fort Wayne, Indiana, Service Center to open in November⁽¹⁾

MONTREAL, Oct. 23, 2026 (GLOBE NEWSWIRE) — Bombardier today announced that it is continuing to significantly enhance its American footprint. The company plans to hire 800 people across America. Today, Bombardier is actively recruiting for 500 positions across the country and plans to create an additional 300 jobs through footprint expansion projects⁽¹⁾. Texas is planned to be the next pillar of expansion and will account for 150 of the 300 new jobs. Hiring activities will further be spread across the company’s U.S. home base in Kansas as well as in Indiana and Connecticut. Job creation in these states will be driven by infrastructure investments, which will total an estimated $270M in the first phase.

“Our American service network is a key pillar of Bombardier’s growth strategy. This new wave of expansion and hiring reflects our long-term confidence in this market and our employees in America,” said Eric Martel, President & CEO, Bombardier. “Based on our constructive conversations with the U.S. administration, we see a bright path forward for our highly skilled aerospace workers as well as a positive environment for Bombardier to continue pursuing direct investments to grow our American footprint.”

Bombardier’s Learning Center in Wichita, Kansas represents one component of Bombardier’s broader investment in this iconic city. Inaugurated last week, the new North American Learning Center reinforces the company’s commitment to developing talent, enhancing capabilities and supporting the long-term growth of its Kansas operations.

Bombardier’s newest American service facility at Fort Wayne International Airport in Fort Wayne, Indiana, is an approximately 64,500-square-foot facility that will accommodate up to six aircraft and offer scheduled and unscheduled maintenance, modifications, avionics installations and AOG support. The company will further launch new footprint expansion projects in Dallas, Texas, and Connecticut.

In 2025, the company’s U.S. activities supported 27,200 American jobs⁽²⁾ throughout its service and manufacturing facilities, as well as within a broad supply chain, where Bombardier spent $2.8 billion. The 27,200 jobs across America, supported by Bombardier activities, carried a 7-to-1 ratio: for every one Bombardier job, activities support seven additional jobs across the economy through supplier purchases and household spending⁽²⁾. Based on current hiring and expansion plans, the total number of jobs supported is projected to exceed 33,000⁽¹⁾.

Bombardier’s American workers are based all around the United States with sites in Kansas, Texas, Arizona, Florida, Connecticut, Illinois, Delaware, California, Washington D.C. and New Jersey, with Bombardier’s overall direct employment presence covering more than 20 states. Bombardier continues to invest in the people, infrastructure and capabilities that support its customers and grow the American aerospace industry.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of approximately 5,300 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.     

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Mark Masluch
+1 (514) 855-7167   
mark.masluch@aero.bombardier.com

(1) Forward-looking statements 
This press release contains certain forward-looking statements. By their nature, forward-looking statements require the Corporation to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from those set forth in the forward-looking statements. Please refer to the “Forward-Looking Statements” disclaimer contained in Bombardier Inc.’s most recently published financial report for additional details.

(2) Oxford Economics study conducted for Bombardier.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0afefc1e-b3ec-492e-bc39-d3befc30c62d

Renk Group AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

23. Oct 2026 / 13:17 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Legal entity

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

• WeRide was named among WICV 2026’s “Top 10 Automotive AI Application Cases of 2026” for its Physical AI flywheel powered by GENESIS and WITT.
• Founder and CEO Dr. Tony Han shared WeRide’s approach to applying L4 autonomous driving technology to L2 advanced driver-assistance systems, emphasizing intelligence density and safety.
• WeRide continues to expand real-world deployment across L2 to L4, with operations in more than 60 cities across 13 countries and an L4 fleet of approximately 3,600 vehicles.

BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, has been named among the “Top 10 Automotive AI Application Cases of 2026” at the 2026 World Intelligent Connected Vehicles Conference (WICV). The recognition highlights WeRide’s innovative Physical AI flywheel powered by WeRide GENESIS and WeRide WITT, demonstrating how the company is translating cutting-edge AI technologies into large-scale commercial applications.

WeRide’s Physical AI flywheel recognised among the “Top 10 Automotive AI Application Cases of 2026”.

The selected case of WeRide’s Physical AI flywheel, highlights the practical application of the collaborative application of cutting-edge AI technologies in autonomous driving development. At its core, the flywheel brings together WeRide GENESIS, WeRide’s proprietary general-purpose simulation model, and WeRide WITT, WeRide’s Physical AI Cognitive Foundation Model. WeRide WITT extracts and validates physical facts from real-world road data, while WeRide GENESIS uses these insights to generate high-fidelity simulation scenarios that adhere to real-world physical laws, strengthening training in complex driving scenarios and long-tail situations. Together, the two models empower vehicle-side models, improve development efficiency and adaptability to complex scenarios, and support the deployment of autonomous driving technology across cities and vehicle platforms.

Focusing on the path to scaled production of autonomous driving, Dr. Tony Han, Founder and CEO of WeRide, delivered a keynote titled “The Critical Leap Toward Scaled Deployment of Autonomous Driving” at the conference’s Key Technology Forum, sharing WeRide’s experience in applying L4 expertise to L2 advanced driver-assistance systems (ADAS).

Dr. Han highlighted “intelligence density” as a key metric for evaluating ADAS solutions: how much intelligence each TOPS of computing power can deliver. The goal is to achieve a higher level of intelligent driving with limited computing resources. He also emphasized that investing in safety is essential to earning user trust and building long-term brand value. As the technology advances and its applications expand, safety must remain a priority at every stage, protecting not only passengers inside the vehicle but also every road user outside it.

WICV 2026 was held in Yizhuang, Beijing, from October 21 to 23, and was co-hosted by China’s Ministry of Industry and Information Technology, Ministry of Transport, and the People’s Government of Beijing Municipality. This year’s conference was themed “Pooling Wisdom, Boundless Connectivity: Advancing Steadily Towards a New Era of Automated Driving”. The conference has been held annually since 2018 and serves as a major industry event for intelligent connected vehicles, as well as an important platform for policy development and international cooperation.

WeRide’s autonomous driving technologies were also showcased in real-world applications during the conference. During WICV 2026, WeRide deployed more than a dozen Robotaxis and Robobuses, providing autonomous ride experiences and shuttle services for attendees. The nearly 7-kilometer Robotaxi experience route started and ended at the main venue, while Robobuses provided shuttle services connecting conference venues and visitor destinations, including Yonghui Building, BAIC BluePark, Rocket Street, and Robot World.

Today, WeRide has commercialized its full-stack autonomous driving technologies spanning L2 to L4, with operations spanning more than 60 cities across 13 countries worldwide. Its L4 autonomous driving fleet comprises approximately 3,600 vehicles, supported by extensive operating experience across different cities and real-world use cases.

WeRide’s autonomous passenger vehicles are already operating publicly in major global cities, including Guangzhou, Beijing, Abu Dhabi, Dubai, Singapore, Riyadh, and Zurich. Through global mobility platforms such as Uber and Grab, as well as local partners including SBB, ioki and TXAI, WeRide is integrating autonomous driving into more urban transportation networks and will soon launch services in additional markets including Spain and Denmark.

WeRide’s L4 autonomous driving technology is also empowering mass-produced passenger vehicles through shared technology architecture. WRD 3.0, WeRide’s one-stage end-to-end L2++ ADAS solution, has been deployed on models including the Chery Exeed Sterra, GAC AION N60, AION i60, and GAC Trumpchi Y7. To date, WRD 3.0 has secured production design wins across more than 30 vehicle models, bringing advanced driving technologies to a broader consumer base.

As the intelligent connected vehicle industry enters a new phase of development, WeRide will continue to advance Physical AI innovation and promote technological synergies across L2 to L4. Working with global industry partners, WeRide will expand the real-world application of its technologies at scale, translating technological progress into safer and more reliable mobility experiences.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been deployed in over 60 cities across 13 countries. We are also the first and only technology company whose products have received autonomous driving permits in nine markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, Spain, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s Change the World lists in 2023, 2025, and 2026, and to the Fortune Future 50 list in 2025.

Media Contact

pr@weride.ai

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7a36dc-21e5-4ca6-a522-9e2ab4a4a2f3

Voluntary Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing

TEL AVIV, Israel, Oct. 23, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that it has initiated a process to voluntarily delist its ordinary shares, no par value per share, from the Tel Aviv Stock Exchange Ltd. (the “TASE”).

In accordance with applicable Israeli law and the rules of the TASE, the last day the ordinary shares will trade on the TASE is expected to be January 25, 2027, and the ordinary shares are expected to be delisted from the TASE on or about January 27, 2027. Shareholders will be able to continue to buy and sell ordinary shares on the TASE in the same manner as has been the case to date until market close on the final day of trading.

The Company’s ordinary shares will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GIXI,” and the Company will also continue to file public reports and disclosures in accordance with the rules and regulations promulgated by the U.S. Securities and Exchange Commission (“SEC”) and Nasdaq. The delisting from the TASE will not affect Gix’s continued listing on Nasdaq in the United States, and all ordinary shares currently traded on the TASE may be transferred to Nasdaq.

The Company’s Board of Directors approved the delisting of the ordinary shares from the TASE and a transition to exclusive trading on Nasdaq with the objective of potentially enhancing liquidity on Nasdaq, and allowing the Company to focus its investor and public relations efforts on the U.S. capital markets.

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is Deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About deliverz.ai

deliverz.ai is defining the future of healthcare logistics automation with an end-to-end, AI-powered orchestration platform that unifies autonomous robots, human transport teams, and hospital workflows into a single intelligent system. Robot-agnostic and built to scale, deliverz.ai automates and optimizes logistics across any workflow and within any environment, increasing throughput, reducing costs, and improving both patient and staff experience. Delivered through a flexible Software as a Service (SaaS) and Robotics as a Service (RaaS) model, deliverz.ai provides the intelligent logistics backbone for hospitals, making operations smarter, faster, and patient-centered. For more information, visit https://www.deliverz.ai

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the voluntary delisting of its ordinary shares from the TASE, including the expected timing of the last trading day and of the delisting; the continued trading of its ordinary shares on Nasdaq; and the expected benefits of the delisting and of exclusive trading on Nasdaq, including potentially enhancing liquidity on Nasdaq and focusing its investor and public relations efforts on the U.S. capital markets. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

Transaction in Own Shares

October 22, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 22 October 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
22/10/2026	1,075,000	£ 39.7050	£ 38.8900	£ 39.3207	LSE	GBP
22/10/2026	–	–	–	–	Chi-X (CXE)	GBP
22/10/2026	–	–	–	–	BATS (BXE)	GBP
22/10/2026	535,000	€ 47.6000	€ 46.5900	€ 47.1506	XAMS	EUR
22/10/2026	–	–	–	–	CBOE DXE	EUR
22/10/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026.

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20261022_Shell RNS – full version

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW.

Preliminary result of the subsequent offer period of S-Bank Plc’s voluntary recommended public cash tender offer for all the shares in Oma Savings Bank Plc

OMA SAVINGS BANK PLC        STOCK EXCHANGE RELEASE      23 October 2026 at 14:05 (EEST)

On 9 July 2026, S-Bank Plc (“S-Bank” or the “Offeror“), announced a voluntary recommended public cash tender offer for all the issued and outstanding shares in Oma Savings Bank Plc (“Oma Savings Bank“) that are not held by Oma Savings Bank or its subsidiaries (the “Shares” or, individually, a “Share“) (the “Tender Offer“). The Offeror has published a tender offer document, dated 16 July 2026, concerning the Tender Offer and the supplements to the tender offer document, dated 14 August 2026, 31 August 2026, 7 September 2026 and 16 September 2026. The offer period under the Tender Offer commenced on 17 July 2026 at 9:30 a.m. (Finnish time) and expired on 25 September 2026 at 4:00 p.m. (Finnish time). On 1 October 2026 at 9:30 a.m. (Finnish time), the Offeror commenced a subsequent offer period (the “Subsequent Offer Period“) in accordance with the terms and conditions of the Tender Offer, which expired on 22 October 2026 at 4:00 p.m. (Finnish time).

Based on the preliminary result of the Subsequent Offer Period, the 162,531 Shares validly tendered during the Subsequent Offer Period represent approximately 0.49 percent of all issued and outstanding shares and votes in Oma Savings Bank (excluding treasury shares). The Shares tendered during the Subsequent Offer Period, together with the Shares tendered during the initial offer period and any Shares otherwise acquired by the Offeror, represent approximately 97.32 percent of all issued and outstanding shares and votes in Oma Savings Bank (excluding treasury shares).

The Offeror will confirm and announce the final result of the Subsequent Offer Period on or about 26 October 2026. The tender offer consideration for the Shares validly tendered during the Subsequent Offer Period is expected to be paid to the shareholders on or about 2 November 2026. The actual timing of the receipt of the tender offer consideration will depend on the schedules for payment transactions between financial institutions.

The Offeror has reserved the right to acquire Shares on or after the date of this release in public trading on Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) or otherwise to the extent permitted by applicable laws and regulations.

ADVISERS

The Offeror has appointed PricewaterhouseCoopers Oy as lead financial adviser, Danske Bank A/S, Finland Branch as arranger of the tender offer, Borenius Attorneys Ltd as legal adviser, and IR Partners Oy as communication advisor in connection with the Tender Offer. Oma Savings Bank has appointed EY Advisory Oy as financial adviser, Krogerus Attorneys Ltd as legal adviser and Rud Pedersen Finland Ltd as communication advisor in connection with the Tender Offer.

Additional information:

Oma Savings Bank Plc

Karri Alameri, CEO, interview requests via Chief Communications Officer

Pirjetta Soikkeli, Chief Communications Officer, tel. +358 40 7500 093, pirjetta.soikkeli@omasp.fi

www.omasp.fi

S-Bank Plc

Riikka Laine-Tolonen, CEO, interview requests via communications

Tiina Nurmi, Chief Communications Officer, tel. +358 10 768 1689, tiina.2.nurmi@s-pankki.fi

S-Bank Communications, tel. +358 10 767 9300, viestinta@s-pankki.fi

Information regarding the Tender Offer is available at www.s-pankki.fi/tenderoffer.

ABOUT OMA SAVINGS BANK

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki.

ABOUT S-BANK

S-Bank is a well-capitalised bank and part of the domestic S Group. S-Bank was created as a bank for co-op members with the mission of ensuring that everyone has the possibility of a little more wealth. S-Bank offers its customers banking, financing and wealth management services and engages in mortgage banking operations. At the end of 2025, S-Bank had more than 3.4 million customers, of which 858,000 were active customers. S-Bank’s strategy is to grow the number of active customers and the share of customers who consolidate their banking activities with S-Bank, and to offer superior ease and benefits through a service model that combines digital and personal service. S-Bank employs approximately 1,200 experts.

IMPORTANT INFORMATION

THIS RELEASE MAY NOT BE RELEASED OR OTHERWISE DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW.

THIS RELEASE IS NOT A TENDER OFFER DOCUMENT AND AS SUCH DOES NOT CONSTITUTE AN OFFER OR INVITATION TO MAKE A SALES OFFER. IN PARTICULAR, THIS RELEASE IS NOT AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES DESCRIBED HEREIN, AND IS NOT AN EXTENSION OF THE TENDER OFFER IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. INVESTORS SHALL ACCEPT THE TENDER OFFER FOR THE SHARES ONLY ON THE BASIS OF THE INFORMATION PROVIDED IN A TENDER OFFER DOCUMENT. OFFERS WILL NOT BE MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE EITHER AN OFFER OR PARTICIPATION THEREIN IS PROHIBITED BY APPLICABLE LAW OR WHERE ANY TENDER OFFER DOCUMENT OR REGISTRATION OR OTHER REQUIREMENTS WOULD APPLY IN ADDITION TO THOSE UNDERTAKEN IN FINLAND.

THE TENDER OFFER IS NOT BEING MADE DIRECTLY OR INDIRECTLY IN ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAW AND, WHEN PUBLISHED, THE TENDER OFFER DOCUMENT AND RELATED ACCEPTANCE FORMS WILL NOT AND MAY NOT BE DISTRIBUTED, FORWARDED OR TRANSMITTED INTO OR FROM ANY JURISDICTION WHERE PROHIBITED BY APPLICABLE LAWS OR REGULATIONS. IN PARTICULAR, THE TENDER OFFER IS NOT BEING MADE, DIRECTLY OR INDIRECTLY, IN OR INTO, OR BY USE OF THE POSTAL SERVICE OF, OR BY ANY MEANS OR INSTRUMENTALITY (INCLUDING, WITHOUT LIMITATION, FACSIMILE TRANSMISSION, TELEX, TELEPHONE OR THE INTERNET) OF INTERSTATE OR FOREIGN COMMERCE OF, OR ANY FACILITIES OF A NATIONAL SECURITIES EXCHANGE OF, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA. THE TENDER OFFER CANNOT BE ACCEPTED, DIRECTLY OR INDIRECTLY, BY ANY SUCH USE, MEANS OR INSTRUMENTALITY OR FROM WITHIN, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA AND ANY PURPORTED ACCEPTANCE OF THE TENDER OFFER RESULTING DIRECTLY OR INDIRECTLY FROM A VIOLATION OF THESE RESTRICTIONS WILL BE INVALID.

THIS STOCK EXCHANGE RELEASE HAS BEEN PREPARED IN COMPLIANCE WITH FINNISH LAW, THE RULES OF NASDAQ HELSINKI AND THE HELSINKI TAKEOVER CODE AND THE INFORMATION DISCLOSED MAY NOT BE THE SAME AS THAT WHICH WOULD HAVE BEEN DISCLOSED IF THIS ANNOUNCEMENT HAD BEEN PREPARED IN ACCORDANCE WITH THE LAWS OF JURISDICTIONS OUTSIDE OF FINLAND.

Information for shareholders of Oma Savings Bank in the United States

Shareholders of Oma Savings Bank in the United States are advised that the Shares are not listed on a U.S. securities exchange and that Oma Savings Bank is not subject to the periodic reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act“), and is not required to, and does not, file any reports with the U.S. Securities and Exchange Commission (the “SEC“) thereunder.

The Tender Offer will be made for the issued and outstanding shares of Oma Savings Bank, which is domiciled in Finland, and is subject to Finnish disclosure and procedural requirements. The Tender Offer is made in the United States pursuant to Section 14(e) and Regulation 14E under the Exchange Act, subject to the exemption provided under Rule 14d-1(c) under the Exchange Act, for a “Tier I” tender offer, and otherwise in accordance with the disclosure and procedural requirements of Finnish law, including with respect to the Tender Offer timetable, settlement procedures, withdrawal, waiver of conditions and timing of payments, which are different from those of the United States. In particular, the financial information included in this announcement has been prepared in accordance with applicable accounting standards in Finland, which may not be comparable to the financial statements or financial information of U.S. companies.

You should note that the Offeror’s ability to waive the conditions to the Tender Offer (both during and after the end of the acceptance period) and the shareholders’ ability to withdraw their acceptances, are not the same under a tender offer governed by Finnish law as under a tender offer governed by U.S. law. U.S. shareholders are encouraged to consult with their own advisors regarding the Tender Offer. In particular, the Offeror may waive conditions to the Tender Offer without offering withdrawal rights, to the extent not required by applicable law.

The Tender Offer is made to Oma Savings Bank’s shareholders resident in the United States on the same terms and conditions as those made to all other shareholders of Oma Savings Bank to whom an offer is made. Any informational documents, including this announcement, are being disseminated to U.S. shareholders on a basis comparable to the method that such documents are provided to Oma Savings Bank’s other shareholders.

To the extent permissible under applicable law or regulations, the Offeror and its affiliates or its brokers and its brokers’ affiliates (acting as agents for the Offeror or its affiliates, as applicable) may from time to time after the date of this stock exchange release and during the pendency of the Tender Offer, and other than pursuant to the Tender Offer, directly or indirectly purchase or arrange to purchase Shares or any securities that are convertible into, exchangeable for or exercisable for Shares. These purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. To the extent information about such purchases or arrangements to purchase is made public in Finland, such information will be disclosed by means of a press release or other means reasonably calculated to inform U.S. shareholders of Oma Savings Bank of such information. In addition, the financial advisers to the Offeror may also engage in ordinary course trading activities in securities of Oma Savings Bank, which may include purchases or arrangements to purchase such securities. To the extent required in Finland, any information about such purchases will be made public in Finland in the manner required by Finnish law.

Neither the SEC nor any U.S. state securities commission has approved or disapproved the Tender Offer, passed upon the merits or fairness of the Tender Offer, or passed any comment upon the adequacy, accuracy or completeness of the disclosure in relation to the Tender Offer. Any representation to the contrary is a criminal offence in the United States.

The receipt of cash pursuant to the Tender Offer by a U.S. holder of Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local, as well as foreign and other, tax laws. Each holder of Shares is urged to consult its independent professional advisers immediately regarding the tax and other consequences of accepting the Tender Offer.

To the extent the Tender Offer is subject to U.S. securities laws, those laws only apply to U.S. holders of Shares and will not give rise to claims on the part of any other person. It may be difficult for Oma Savings Bank’s shareholders to enforce their rights and any claims they may have arising under the U.S. federal securities laws, since the Offeror and Oma Savings Bank are located in non-U.S. jurisdictions and some or all of their respective officers and directors may be residents of non-U.S. jurisdictions. Oma Savings Bank shareholders may not be able to sue the Offeror or Oma Savings Bank or their respective officers or directors in a non-U.S. court for violations of the U.S. federal securities laws. It may be difficult to compel the Offeror and Oma Savings Bank and their respective affiliates to subject themselves to a U.S. court’s judgment.

Forward-looking statements

This release contains statements that, to the extent they are not historical facts, constitute “forward-looking statements”. Forward-looking statements include statements concerning plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, business strategy and the trends in the industries and the political and legal environment and other information that is not historical information. In some instances, they can be identified by the use of forward-looking terminology, including the terms “believes”, “intends”, “may”, “will” or “should” or, in each case, their negative or variations on comparable terminology. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements contained herein speak only as at the date of this release.

Disclaimer

PricewaterhouseCoopers Oy is acting as financial adviser to the Offeror and no-one else in connection with this announcement. Neither PricewaterhouseCoopers Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than the Offeror for providing the protections afforded to clients of PricewaterhouseCoopers Oy or for providing advice in connection with any matters referred to in this announcement.

Danske Bank A/S is authorised under Danish banking law. It is subject to supervision by the Danish Financial Supervisory Authority. Danske Bank A/S is a private, limited liability company incorporated in Denmark with its head office in Copenhagen where it is registered in the Danish Commercial Register under number 61126228.

Danske Bank A/S (acting via its Finland Branch) is acting as arranger for the benefit of the Offeror and no other person in connection with these materials or their contents. Danske Bank A/S will not be responsible to any person other than the Offeror for providing any of the protections afforded to clients of Danske Bank A/S, nor for providing any advice in relation to any matter referred to in these materials. Without limiting a person’s liability for fraud, Danske Bank A/S, nor any of its affiliates nor any of its respective directors, officers, representatives, employees, advisers or agents shall have any liability to any other person (including, without limitation, any recipient) in connection with the Tender Offer.

EY Advisory Oy is acting exclusively for Oma Savings Bank Plc and no one else in connection with the Tender Offer and the matters set out in this announcement. Neither EY Advisory Oy nor its affiliates, nor their respective partners, directors, officers, employees or agents are responsible to anyone other than Oma Savings Bank for providing the protections afforded to clients of EY Advisory Oy, or for giving advice in connection with the Tender Offer or any matter or arrangement referred to in this announcement.

PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^® 3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty^™ Percutaneous 3D Bunion Correction System, and the SpeedMTP^® System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide^® patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

SHENZHEN, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — Nexpu Ltd. (Nasdaq: DPU) (“Nexpu” or the “Company”) today announced that its subsidiary, Top Kingwin Technology INC, has launched a customizable music creation platform, branded as DPU (the “DPU Platform”), designed to help users create songs and instrumental tracks based on their own ideas, lyrics and preferred musical styles.

Short-form videos, social media and digital storytelling increasingly rely on music as part of everyday content creation. The DPU Platform integrates third-party AI technology with the Company’s proprietary AI models, including its DPU-related model, to offer users a platform for music creation, listening and sharing.

Turning Ideas into Personalized Music

DPU Platform offers two creation modes. In description mode, users enter a musical style and theme, with the option to generate instrumental music. In lyrics mode, users provide lyrics, select or customize a musical style, and enter a song title.

Users can preview generated tracks within the creation interface, edit titles and cover images, download selected works, and publish their music within the platform for other users to view.

These features allow users to experiment with different musical styles and develop tracks based on their own preferences for song ideas or other digital content.

Connecting Creation, Discovery and Sharing

Beyond music creation, DPU Platform provides discovery by musical style and tags, personal libraries for managing works, and account and membership management. Chinese- and English-language interfaces are available.

The platform’s membership and usage-credit framework provide a foundation for tiered services. Specific features, access and usage allowances are governed by the applicable membership terms. Commercial use of generated or uploaded content remains subject to platform terms, third-party licenses and applicable intellectual property requirements.

Expanding Nexpu’s Software Portfolio

The launch adds a customizable music application to Nexpu’s software portfolio through Top Kingwin Technology INC, reflecting the group’s continued development of software products for user applications.

Top Kingwin Technology INC intends to refine DPU Platform through user feedback and ongoing product development. Future enhancements and commercial expansion will depend on user demand, technical performance and applicable licensing requirements.

This press release contains forward-looking statements. Please see the “Safe Harbor Statement” below for additional information.

About Nexpu Ltd. (formerly known as Top KingWin Ltd)

Nexpu Ltd. (formerly known as Top KingWin Ltd) engages in the following business activities: (i) the sale of devices that support data collection and analysis; (ii) the sale of robots; and (iii) the development and operation of software products and platforms.

Safe Harbor Statement

This announcement contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. These statements are based on management’s current expectations as of the date of this release and are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: the DPU Platform is newly launched and may not perform as intended or achieve anticipated user adoption or commercial success; the platform’s functionality and performance may depend on third-party AI technologies, services and infrastructure; the Company may encounter technical challenges, intellectual property or licensing issues, or regulatory uncertainties in connection with the development, operation and commercialization of the platform; planned enhancements and future commercial expansion may not materialize as anticipated; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For further information, please contact:

Bonnie Zhang

Email: IR@tcjhgw.cn

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Atari (Euronext Paris: ALATA; OTCQX: PONGF), an interactive entertainment company, has qualified to trade on the OTCQX® Best Market.

Atari begins trading today on OTCQX under the symbol “PONGF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Atari is one of the most recognized and celebrated brands in the world. Their team is dedicated to honoring the legacy of the brand, and building upon its success so that Atari continues to be associated with fun for years to come.

Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

“Moving to OTCQX is an important milestone for Atari and a practical step that gives U.S. investors real-time quotes and more convenient access to Atari shares,” said Wade Rosen, Chairman and CEO of Atari.

“We are excited to welcome Atari to the OTCQX Market,” said Jonathan Dickson, VP, Head of EMEA at OTC Markets Group. “As one of the world’s most iconic consumer brands and interactive entertainment producers, Atari’s addition to OTCQX enhances U.S. investors’ ability to access global brands and strengthens the connection between European and U.S. capital markets.”

Trading in European securities on OTC Markets reached $97.45 billion in the third quarter of 2026, representing an 23.37% increase over Q3 2025. OTC Markets recorded $656.81 billion in total dollar volume in the first three quarters of the year. Europe ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Atari
Atari is an interactive entertainment company and an iconic gaming industry brand that transcends generations and audiences. The company is globally recognized for its multi-platform, interactive entertainment and licensed products. Atari owns and/or manages a portfolio of more than 400 unique games and franchises, including world-renowned brands like Asteroids®, Centipede®, Missile Command®, Pong®, and RollerCoaster Tycoon®.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com